GlassScriptPhysician profile
David Kavtaradze
NPI 1376516484
$18,546.24
in general payments reported to CMS, 2019-2025
50 companies · $854 in 2025
The $854 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,220 · 2020: $1,638 · 2021: $1,816 · 2022: $1,769 · 2023: $1,826 · 2024: $1,423 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,009 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,009.28 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8,097.74 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,896.70 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,218.72 | 2019-2025 | |
| Novo Nordisk INC | $1,172.88 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,118.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Lilly USA, LLC | $725.35 | 2019-2025 | Mounjaro, Amyvid, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $583.22 | 2022-2025 | |
| Biofire Diagnostics, LLC | $368.25 | 2019-2020 | |
| Astellas Pharma US INC | $328.90 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $320.19 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $298.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $243.15 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $196.66 | 2019-2022 | |
| Amgen INC. | $171.67 | 2019-2021 | |
| Antares Pharma, INC. | $132.45 | 2022-2025 | Xyosted |
Show all 46 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kavtaradze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.